The Acetaminophen and Caffeine combination (Cafedon) is primarily used to provide supportive symptomatic relief across various mild to moderate pain and febrile conditions. This combination is relevant in contexts marked by increased discomfort or tension, offering supportive therapeutic benefit in acute situations where short-term symptomatic assistance is needed to help manage difficult episodes.

---

Symptomatic Relief Domains

Cafedon helps address symptom clusters of discomfort arising from common sources, including tension headaches, acute migraine attacks, backache, toothache, and recurrent pains like dysmenorrhea (menstrual pain). This medication is also applied across domains where additional symptomatic support is needed for the aches, pains, and elevated body temperature (feverishness) associated with colds and influenza. It is relevant when symptoms become more noticeable and supports the management of episodes of heightened discomfort.

“This formulation is commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate.”

---

Note on Symptom Management

Quick Fact: Relief for Episodic Pain and Fever The medicine may assist with maintaining functional stability by offering dual symptomatic relief, and may contribute to easing the overall symptom load associated with these acute, non-chronic manifestations.

Regulatory References

1. NIH MedlinePlus overview of Analgesic Adjuvants

Regulatory documents define population eligibility for Cafedon based on age, organ function, and specific medical conditions.

Eligibility Scope

Eligibility Status	Populations
Allowed Use	Adults and adolescents 12 years of age and older are approved for use under standard labeled conditions [Health Canada; NIH DailyMed].
Contraindicated	Patients with known hypersensitivity to Acetaminophen or Caffeine, severe hepatic impairment or active liver disease, and individuals with Porphyria must not use this medicine [FDA; NIH DailyMed].
Not Recommended	Use is not recommended for children younger than 12 years of age for self-medication, as safety and efficacy are not established in this group [Health Canada].

Conditional Use Requirements

Eligibility is conditional for certain populations due to increased risk:

• Organ Function: Patients with impaired renal function or any underlying liver disease must consult a healthcare professional, and those with severe impairment are often restricted [NIH DailyMed].
• Lifestyle: Individuals who consume three or more alcoholic drinks daily are cautioned against use due to a documented increase in the risk of severe liver damage [FDA].
• Physiological State: Pregnant and lactating individuals should consult a healthcare professional before use; official labeling often classifies this status as not recommended due to the components passing into breast milk [TGA; NIH DailyMed].
• Comorbidities: Caution is required for patients with high blood pressure, glaucoma, or a history of gastrointestinal conditions like stomach ulcers [Health Canada; NIH DailyMed].

Official regulatory statements determine who is eligible to use Cafedon by establishing absolute contraindications and mandatory conditional use rules for specific age and health categories.

Interactions with other medicines and products for Cafedon are documented across pharmacokinetic, pharmacodynamic, and substance categories. Regulatory constraints prohibit the co-administration of Cafedon with any other product containing acetaminophen due to the major risk of unintentional overdose and subsequent liver damage.

Pharmacokinetic and Exposure Interactions

The clearance of the Caffeine component may be significantly reduced by strong CYP1A2 inhibitors such as Fluvoxamine, leading to increased plasma concentrations. Conversely, the absorption of the Acetaminophen component may be increased by prokinetic agents like Metoclopramide or reduced by ion-exchange resins such as Cholestyramine, which may require a timing separation of at least one hour in administration. Enzyme-inducing medicines like Carbamazepine and Phenytoin increase the potential for Acetaminophen hepatotoxicity by enhancing the formation of toxic metabolites. Oral contraceptives may also increase the rate of clearance of Acetaminophen.

Pharmacodynamic and Substance Interactions

A clinically significant pharmacodynamic interaction exists with Warfarin and other coumarin anticoagulants, where prolonged, regular daily use of the acetaminophen component may enhance the anticoagulant effect and increase the risk of bleeding. The co-administration with other central nervous system stimulants may result in additive pharmacodynamic effects, including increased heart rate and blood pressure. The alcohol interaction is classified as a major risk, as chronic consumption of three or more alcoholic drinks daily significantly increases the documented potential for severe acetaminophen-induced liver damage, especially in patients with pre-existing hepatic impairment.

Cafedon is a pharmaceutical combination containing paracetamol (acetaminophen) and caffeine. The mechanism of action involves the synergistic effects of these two compounds.

The paracetamol component modulates pain signaling primarily through the inhibition of cyclooxygenase enzymes (COX), particularly in the central nervous system (CNS), reducing the synthesis of pro-inflammatory prostaglandins. This action decreases the central generation of pain signals. The precise primary molecular target for paracetamol remains subject to investigation but is linked to COX-2 and COX-3 pathways, with minimal peripheral anti-inflammatory activity.

The caffeine component acts as a non-selective competitive antagonist at all four adenosine receptor subtypes ( A1, A2 A, A2 B, and A3), particularly within the CNS. Antagonism of A1 and A2 A receptors prevents the inhibitory effects of endogenous adenosine on neurotransmitter release. This leads to an increase in the extracellular concentration and release of various excitatory neurotransmitters, including dopamine and norepinephrine, which modulates system-level physiological consequences such as enhanced alertness. Caffeine is also reported to potentiate the central analgesic effects of paracetamol, which is theorized to occur through an unknown central intracellular mechanism involving adenosine receptor antagonism or direct effects on cAMP and mTOR signaling pathways in specific cells.

The usage instructions for Cafedon, which typically contains Paracetamol and Caffeine, are defined by established product guidelines. These instructions standardize the correct route of administration, dosage limits, and frequency of use, ensuring adherence to the approved usage protocol.

Official Administration Guidelines

Administration Scope	Instructions
Route of Administration	For oral use only. The tablets should be swallowed whole, typically with water.
Dosing Frequency	Doses must not be repeated more frequently than every 4 hours.
Preparation	No preparation steps (such as reconstitution or dilution) are required, as it is an immediate-release tablet.

Dosage and Age-Specific Rules

The dosage schedule establishes a clear maximum single dose and a strict 24-hour limit to govern consumption, as detailed in the verified product information.

Patient Population	Maximum Single Dose	Maximum Daily Dose (24 hours)
Adults (16 years and over)	Two tablets	Eight tablets
Adolescents (12 to 15 years)	One tablet	Four tablets
Children (Under 12 years)	Not recommended for use.	Not recommended for use.

The core procedural structure is to take the defined single dose and then observe a minimum waiting period of four hours before the next administration, always ensuring that the total number of tablets taken within a 24-hour cycle does not exceed the mandatory maximum limit. This protocol must be followed exactly as written on the product label.

The research evidence used to describe the combination of Acetaminophen and Caffeine is documented in official regulatory sources and peer-reviewed scientific literature. The studies focus on characterizing the combination’s role in research exploring how acute pain and headache symptoms change over time.

Evidence from Studies on Primary Headaches

The evidence base consists primarily of short-term Randomized Controlled Trials (RCTs) and systematic reviews. For episodic tension-type headaches, research monitored changes in self-reported pain intensity, typically focusing on whether participants achieved a pain-free status within the first few hours following a single dose. Similar studies were conducted for acute mild to moderate migraine attacks, where researchers also assessed changes in associated symptoms like light sensitivity. Findings describe patterns observed in these studies, including differences in pain relief measurements when compared to placebo. The evidence is largely focused on the immediate, acute phase of a headache episode.

---

Evidence on the Analgesic Adjuvant Effect

Research has been conducted across various acute pain models, such as post-dental procedure pain, to understand the role of caffeine as an adjuvant (a compound that enhances the action of another). These meta-analyses and trials examined the difference in pain relief metrics when the caffeine component was included compared to acetaminophen alone. Studies contribute to the broader evidence landscape regarding the role of caffeine as an adjuvant. This research demonstrates that the pooled evidence is drawn from studies across heterogeneous pain models.

---

Research Gaps and Limitations

A key limitation is that follow-up durations were limited across most pivotal trials, focusing predominantly on single-dose outcomes over a few hours. The current data are insufficient to characterize how findings translate to ongoing, chronic use patterns. Furthermore, the evidence is largely focused on the adult population, and study populations are limited for specific subgroups, including older adults and children.

Key Studies & References Acetaminophen and Caffeine: Overview of Indications, Dosage, and Safety Information (NIH/MedlinePlus)

How to Store and Dispose of Cafedon

Official Storage Requirements

Cafedon tablets must be stored according to official regulatory labeling to maintain stability. The product requires a cool and dry place, with the maximum required storage temperature typically specified as below 25 C or below 30 C.

The medicine must be stored in its original package and protected from light and moisture for the full labeled shelf life. It is mandatory that the product be stored out of the sight and reach of children.

Disposal Instructions

Regulatory documents state there are no special requirements for the disposal of the unused medicinal product. Expired or unused tablets should generally not be discarded in wastewater. If a drug take-back program is unavailable, general federal guidance advises mixing the medicine with an undesirable substance before discarding it in the household trash.